Zachary Hartman

Overview:

My research interests encompass studies of immunity and inflammation in the context of developing and established cancers. These research interests involve studies of inflammation in the genesis and maintenance of specific cancer types (principally breast and ovarian), as well as the impact of inflammation on tumor metastasis and the tumor microenvironment.  My group is also involved in strategies to modulate the immune response to tumors, which involves the use of novel immunotherapeutic strategies and development of vaccines to specific oncogenic targets.  The major focus of my lab is in uncovering strategies to modulate tumor-derived inflammation and tumor-specific immunity that will translate into clinically efficacious therapies in patients.

Positions:

Associate Professor in Surgery

Surgery, Surgical Sciences
School of Medicine

Assistant Professor in Immunology

Integrative Immunobiology
School of Medicine

Associate Professor in Pathology

Pathology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

Ph.D. 2006

Duke University

Postdoctoral Fellow

Duke University

Postdoctoral Fellow, Md Anderson Cancer Center

University of Texas Medical School, Houston

Grants:

A Neoepitope Subunit Vaccine Targeting the Mutated Estrogen Receptor Ligand Binding Domain to Treat and Prevent Endocrine Resistant ER+ Breast Cancer

Administered By
Surgery, Surgical Sciences
Awarded By
Department of Defense
Role
Principal Investigator
Start Date
End Date

Study of LAMP Vaccines in HER2+ Breast Cancer

Administered By
Surgery, Surgical Sciences
Awarded By
Immunomic Therapeutics, Inc.
Role
Principal Investigator
Start Date
End Date

Investigation of stimulating stress response mechanisms to enhance antibody dependent cellular phagocytosis

Administered By
Surgery, Surgical Sciences
Awarded By
Bantam Pharmaceutical, LLC
Role
Principal Investigator
Start Date
End Date

Investigating the adaptive immune response to dormant tumor cells

Administered By
Surgery, Surgical Sciences
Awarded By
American Cancer Society, Inc.
Role
Principal Investigator
Start Date
End Date

Investigation of LAMP anti-tumor vaccines

Administered By
Surgery, Surgical Sciences
Awarded By
Immunomic Therapeutics, Inc.
Role
Principal Investigator
Start Date
End Date

Publications:

Supplementary File 1 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

<jats:p>&lt;p&gt;Supplementary File 1.&lt;/p&gt;</jats:p>
Authors
Ginzel, JD; Acharya, CR; Lubkov, V; Mori, H; Boone, PG; Rochelle, LK; Roberts, WL; Everitt, JI; Hartman, ZC; Crosby, EJ; Barak, LS; Caron, MG; Chen, JQ; Hubbard, NE; Cardiff, RD; Borowsky, AD; Lyerly, HK; Snyder, JC
URI
https://scholars.duke.edu/individual/pub1571959
Source
crossref
Published Date
DOI
10.1158/1541-7786.22526381.v1

Movie 5 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

<jats:p>&lt;p&gt;d16HER2 mammary intraepithelial neoplasm. d16HER2 shown in magenta. Krt14 antibody staining shown in green.&lt;/p&gt;</jats:p>
Authors
Ginzel, JD; Acharya, CR; Lubkov, V; Mori, H; Boone, PG; Rochelle, LK; Roberts, WL; Everitt, JI; Hartman, ZC; Crosby, EJ; Barak, LS; Caron, MG; Chen, JQ; Hubbard, NE; Cardiff, RD; Borowsky, AD; Lyerly, HK; Snyder, JC
URI
https://scholars.duke.edu/individual/pub1571975
Source
crossref
Published Date
DOI
10.1158/1541-7786.22526405

Supplementary Table 1 from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils

<jats:p>&lt;p&gt;CRISPR screen results&lt;/p&gt;</jats:p>
Authors
Trotter, TN; Shuptrine, CW; Tsao, L-C; Marek, RD; Acharya, C; Wei, J-P; Yang, X-Y; Lei, G; Wang, T; Lyerly, HK; Hartman, ZC
URI
https://scholars.duke.edu/individual/pub1571711
Source
crossref
Published Date
DOI
10.1158/0008-5472.22423278.v1

Figure S1 from Vaccine-Induced Memory CD8&lt;sup&gt;+&lt;/sup&gt; T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study

<jats:p>&lt;p&gt;Patient cohort schematic&lt;/p&gt;</jats:p>
Authors
Crosby, EJ; Gwin, W; Blackwell, K; Marcom, PK; Chang, S; Maecker, HT; Broadwater, G; Hyslop, T; Kim, S; Rogatko, A; Lubkov, V; Snyder, JC; Osada, T; Hobeika, AC; Morse, MA; Lyerly, HK; Hartman, ZC
URI
https://scholars.duke.edu/individual/pub1571749
Source
crossref
Published Date
DOI
10.1158/1078-0432.22472862.v1

Movie 4 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

<jats:p>&lt;p&gt;p95HER2 microinvasive carcinoma. p95HER2 shown in magenta. Krt14 antibody staining shown in green.&lt;/p&gt;</jats:p>
Authors
Ginzel, JD; Acharya, CR; Lubkov, V; Mori, H; Boone, PG; Rochelle, LK; Roberts, WL; Everitt, JI; Hartman, ZC; Crosby, EJ; Barak, LS; Caron, MG; Chen, JQ; Hubbard, NE; Cardiff, RD; Borowsky, AD; Lyerly, HK; Snyder, JC
MLA Citation
URI
https://scholars.duke.edu/individual/pub1571960
Source
crossref
Published Date
DOI
10.1158/1541-7786.22526411.v1